<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864096</url>
  </required_header>
  <id_info>
    <org_study_id>MAST 01</org_study_id>
    <nct_id>NCT01864096</nct_id>
  </id_info>
  <brief_title>The Metformin Active Surveillance Trial (MAST) Study</brief_title>
  <acronym>MAST</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to see if metformin can delay the time to progression in men with low risk
      prostate cancer when compared to a placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 years</time_frame>
    <description>Time to progression - progression is defined as the earliest of the following events:
Primary therapy for prostate cancer (e.g. prostatectomy, radiation, hormonal therapy)
Pathological progression as defined as one of the following:
i. At least 4 cores involved ii. At least 50% of any one core involved iii. Gleason pattern 4 or higher</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to primary therapy for prostate cancer</measure>
    <time_frame>3 years</time_frame>
    <description>Length of time before the participants move on to more radical treatment options (prostatectomy, radiation and/or hormonal therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pathological progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in disease-related patient anxiety</measure>
    <time_frame>3 years</time_frame>
    <description>Measured by the Memorial Anxiety Scale for Prostate Cancer (MAX-PC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in decisional satisfaction and decisional conflict</measure>
    <time_frame>3 years</time_frame>
    <description>Measured by the Decisional Regret scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in prostate cancer diagnosis at repeat biopsy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gleason Score at repeat biopsy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical stage of prostate cancer based on digital rectal examination</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the prognostic and predictive value of prostate cancer biomarkers</measure>
    <time_frame>3 years</time_frame>
    <description>Using biomarkers in tissue, blood and urine samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and incidence of (serious) adverse events from the administration of 36 months of metformin to men with early stage prostate cancer</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">408</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Metformin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be male &gt; 18 and &lt; 80 years of age

          2. Have biopsy proven, low-risk, localized prostate cancer choosing expectant management
             as primary treatment ≤ 1year. [For the purposes of assessing subject eligibility a
             diagnostic biopsy must have included at least 10 cores, &lt; 3 cores positive and &lt; 50%
             of any one core positive) and must have been obtained within 6 months of screening].
             Initial diagnosis of T1a/T1b obtained during a TURP is not allowed

          3. Gleason score ≤ 6 [Gleason pattern 4 or above must not be present on any biopsy
             (initial or entry)]

          4. Clinical stage T1c-T2a

          5. Serum PSA ≤10 ng/mL (prior to biopsy)

          6. Life expectancy greater than 5 years, as judged by the treating clinician/urologist

          7. Able to swallow and retain oral medication

          8. Hemoglobin A1c &lt; 6.5%

          9. Able and willing to participate in the full 3 years of the study

         10. Able to understand instructions related to study procedures

         11. Able to read and write (health outcome questionnaires are self-administered),
             understand instructions related to study procedures and give written informed consent

        Exclusion Criteria:

          1. Subject that has ever been treated for prostate cancer with any of the following:

               -  Radiotherapy (external beam or brachytherapy)

               -  Chemotherapy

               -  Hormonal therapy (e.g., megestrol, medoxyprogesterone, cyproterone)

               -  Oral glucocorticoids

               -  GnRH analogues (e.g., leuprolide, goserelin, degarelix)

          2. Current and/or previous use of the following medications:

               -  Use of 5α-reductase inhibitors (eg. Finasteride, Dutasteride) within the past 6
                  months of screening

               -  Drugs with antiandrogenic properties (e.g., flutamide, bicalutamide,
                  ketoconazole, progestational agents) within 6 months prior to screening

          3. Previous or current diagnosis of type 1 or type 2 diabetes

          4. Exposure to metformin within 12 months of screening

          5. Planned or concurrent use of metformin hydrochloride, sulfonylureas,
             thiazolidinediones, or insulin for any reason

          6. Known hypersensitivity or intolerance to metformin hydrochloride

          7. Any condition associated with increased risk of metformin hydrochloride-associated
             lactic acidosis (e.g. congestive heart failure defines as NYHA class III or IV,
             history of any type of acidosis, habitual intake of ≥ 4 alcoholic beverages per day)

          8. Subject has had prior prostatic surgery including TUNA, TURP, TUIP, laser treatment,
             thermotherapy, balloon dilatation, prosthesis, and ultrasound ablation within 3 months
             of screening

          9. Participation in any investigational or marketed drug trial within 30 days prior to
             screening or anytime during the study period. This includes any interventional or
             exercise trials

         10. Any unstable serious co-existing medical condition(s) including, but not limited to,
             myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,
             clinically evident congestive heart failure, or cerebrovascular accident within 6
             months prior to Screening visit

         11. Abnormal liver function test:

               -  Total bilirubin &gt; 1.8 X institutional upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST) &gt; 1.8 X institutional ULN

               -  Alanine aminotransferase (ALT) &gt; 1.8 X institutional ULN

               -  Alkaline phosphatase (ALP) &gt; 1.8 X institutional ULN

         12. Serum creatinine &gt; 1.8 X ULN

         13. History of other malignancies, with the exception of adequately treated nonmelanoma
             skin cancer, stage I melanoma, NMIBC or other solid tumors curatively treated with no
             evidence of disease for at least 5 years

         14. History or current evidence of substance abuse, as defined in DSM-IV, within 12 months
             of screening

         15. History of any illness (including psychiatric) that, in the opinion of the
             investigator, might confound the results of the study or pose additional risk to the
             subject

         16. No other concurrent metformin hydrochloride, sulfonylureas, thiazolidinediones, or
             insulin for any reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Fleshner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network: Department of Surgical Oncology (Urology)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Joshua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network: Department of Surgical Oncology (Urology)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miran Kenk, PhD</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>3431</phone_ext>
    <email>miran.kenk@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele Petrovic, BSc</last_name>
    <phone>(416) 946-4501</phone>
    <phone_ext>5259</phone_ext>
    <email>michele.petrovic@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Manitoba Cancer Care Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Darrel Drachenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CDHA - Victoria Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B2H 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ricardo Rendon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster Institute of Urology-St .Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bobby Shayegan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Appled Urologic Research, Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Leveridge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre-Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathan Izawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute (The Ottawa Hospital)</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rodney Breau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurence Klotz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neil Fleshner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Joshua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre L'Hopitalie de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fred Saad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUHC - Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Simon Tanguay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 3H5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsie Morneau, BSN</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12827</phone_ext>
      <email>emorneau.chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Patrick Richard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Urology Institute</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Fairey, FRCSC, MD, MSc.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2013</study_first_submitted>
  <study_first_submitted_qc>May 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized</keyword>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>metformin</keyword>
  <keyword>active surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

